Mitochondrial disorders in renal tumors

Mitochondrion

Volumn 6, Issue 3, 2006, Pages 105-117

  Hervouet, Eric ^a   Godinot, Catherine ^a  

^a CNRS   (France)

Author keywords

Clear cell renal carcinoma; Fumarate hydratase; Hypoxia inducible factor; Kidney cancer; Mitochondria; Oncocytoma; Reactive oxygen species; Succinate dehydrogenase

Indexed keywords

ALPHA INTERFERON; ANTIMITOTIC AGENT; BEVACIZUMAB; BROMOPYRUVIC ACID; DEOXYGLUCOSE; INTERLEUKIN 2; NEUTRALIZING ANTIBODY; OXYGEN; PACLITAXEL; PARATHYROID HORMONE; PYRUVIC ACID DERIVATIVE; SORAFENIB; SUNITINIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; VATALANIB;

CANCER CELL; CANCER RESEARCH; CANCER RESISTANCE; CARCINOGENESIS; CELL ENERGY; CELL RESPIRATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOWN REGULATION; DRUG BINDING; ENERGY YIELD; FERMENTATION; GLYCOLYSIS; HISTORY OF MEDICINE; HUMAN; KIDNEY FUNCTION; KIDNEY TUMOR; METABOLIC DISORDER; METASTASIS; MITOCHONDRION; NONHUMAN; ONCOCYTOMA; PRIORITY JOURNAL; REVIEW;

ANOXIA; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOLYSIS; HUMANS; KIDNEY NEOPLASMS; MITOCHONDRIA; MITOCHONDRIAL DISEASES; MODELS, BIOLOGICAL; REACTIVE OXYGEN SPECIES;

EID: 33745034691     PISSN: 15677249     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mito.2006.03.003     Document Type: Review

References (125)

1. Achanta G., Sasaki R., Feng L., Carew J.S., Lu W., Pelicano H., Keating M.J., and Huang P. Novel role of p53 in maintaining mitochondrial genetic stability through interaction with DNA Pol gamma. Eur. Mol. Biol. Org. J. 24 (2005) 3482-3492
2. Agani F.H., Pichiule P., Carlos Chavez J., and LaManna J.C. Inhibitors of mitochondrial complex I attenuate the accumulation of hypoxia-inducible factor-1 during hypoxia in Hep3B cells. Comp. Biochem. Physiol. A Mol. Integr. Physiol. 132 (2002) 107-109
3. Amatschek S., Koenig U., Auer H., Steinlein P., Pacher M., Gruenfelder A., Dekan G., Vogl S., Kubista E., Heider K.H., Stratowa C., Schreiber M., and Sommergruber W. Tissue-wide expression profiling using cDNA subtraction and microarrays to identify tumor-specific genes. Cancer Res. 64 (2004) 844-856
4. Amin M.B., de Peralta-Venturina M.N., Ro J.Y., El-Naggar A., Mackay B., Ordonez N., Mani A., and Ayala A. Clear cell sarcoma of kidney in an adolescent and in young adults: a report of four cases with ultrastructural, immunohistochemical, and DNA flow cytometric analysis. Am. J. Surg. Pathol. 23 (1999) 1455-1463
5. Amuthan G., Biswas G., Zhang S.Y., Klein-Szanto A., Vijayasarathy C., and Avadhani N.G. Mitochondria-to-nucleus stress signaling induces phenotypic changes, tumor progression and cell invasion. Eur. Mol. Biol. Org. J. 20 (2001) 1910-1920
6. Amuthan G., Biswas G., Ananadatheerthavarada H.K., Vijayasarathy C., Shephard H.M., and Avadhani N.G. Mitochondrial stress-induced calcium signaling, phenotypic changes and invasive behavior in human lung carcinoma A549 cells. Oncogene 21 (2002) 7839-7849
7. Baby S.M., Roy A., and Lahiri S. Role of mitochondria in the regulation of hypoxia-inducible factor-1alpha in the rat carotid body glomus cells. Histochem. Cell Biol. 124 (2005) 69-76
8. Bardos J.I., and Ashcroft M. Negative and positive regulation of HIF-1: a complex network. Biochim. Biophys. Acta 1755 (2005) 107-120
9. Baysal B.E., Ferrell R.E., Willett-Brozick J.E., Lawrence E.C., Myssiorek D., Bosch A., van der Mey A., Taschner P.E., Rubinstein W.S., Myers E.N., Richard III C.W., Cornelisse C.J., Devilee P., and Devlin B. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 287 (2000) 848-851
10. Baysal B.E., Rubinstein W.S., and Taschner P.E. Phenotypic dichotomy in mitochondrial complex II genetic disorders. J. Mol. Med. 79 (2001) 495-503
11. Behrend L., Mohr A., Dick T., and Zwacka R.M. Manganese superoxide dismutase induces p53-dependent senescence in colorectal cancer cells. Mol. Cell Biol. 25 (2005) 7758-7769
12. Berra E., Ginouves A., and Pouyssegur J. The hypoxia-inducible-factor hydroxylases bring fresh air into hypoxia signalling. Eur. Mol. Biol. Org. Rep. 7 (2006) 41-45
13. Bianchi N.O., Bianchi M.S., and Richard S.M. Mitochondrial genome instability in human cancers. Mutat. Res. 488 (2001) 9-23
14. Brandon M.C., Lott M.T., Nguyen K.C., Spolim S., Navathe S.B., Baldi P., and Wallace D.C. MITOMAP: a human mitochondrial genome database-2004 update. Nucleic Acids Res. 33 (2005) D611-D613
15. Burdon R.H., Alliangana D., and Gill V. Hydrogen peroxide and the proliferation of BHK-21 cells. Free Radic. Res. 23 (1995) 471-486
16. Caldwell M.C., Hough C., Furer S., Linehan W.M., Morin P.J., and Gorospe M. Serial analysis of gene expression in renal carcinoma cells reveals VHL-dependent sensitivity to TNFalpha cytotoxicity. Oncogene 21 (2002) 929-936
17. Cuezva J.M., Krajewska M., de Heredia M.L., Krajewski S., Santamaria G., Kim H., Zapata J.M., Marusawa H., Chamorro M., and Reed J.C. The bioenergetic signature of cancer: a marker of tumor progression. Cancer Res. 62 (2002) 6674-6681
18. Curti B.D. Renal cell carcinoma. J. Am. Med. Assoc. 292 (2004) 97-100
19. Dalgard C.L., Lu H., Mohyeldin A., and Verma A. Endogenous 2-oxoacids differentially regulate expression of oxygen sensors. Biochem. J. 380 (2004) 419-424
20. Dang C.V., and Semenza G.L. Oncogenic alterations of metabolism. Trends. Biochem. Sci. 2 (1999) 68-72
21. Deguchi M., Shiina H., Igawa M., Kaneuchi M., Nakajima K., and Dahiya R. DNA mismatch repair genes in renal cell carcinoma. J. Urol. 169 (2003) 2365-2371
22. Dias N., and Bailly C. Drugs targeting mitochondrial functions to control tumor cell growth. Biochem Pharmacol 70 (2005) 1-12
23. Di Mauro S. The many faces of mitochondrial diseases. Mitochondrion 4 (2004) 799-807
24. Eng C., Kiuru M., Fernandez M.J., and Aaltonen L.A. A role for mitochondrial enzymes in inherited neoplasia and beyond. Nat. Rev. Cancer 3 (2003) 193-202
25. Enomoto N., Koshikawa N., Gassmann M., Hayashi J., and Takenaga K. Hypoxic induction of hypoxia-inducible factor-1alpha and oxygen-regulated gene expression in mitochondrial DNA-depleted HeLa cells. Biochem. Biophys. Res. Commun. 297 (2002) 346-352
26. Erlandson R.A., Shek T.W., and Reuter V.E. Diagnostic significance of mitochondria in four types of renal epithelial neoplasms: an ultrastructural study of 60 tumors. Ultrastruct. Pathol. 21 (1997) 409-417
27. Faure Vigny H., Heddi A., Giraud S., Chautard D., and Stepien G. Expression of oxidative phosphorylation genes in renal tumors and tumoral cell lines. Mol. Carcinog. 16 (1996) 165-172
28. Foury F., Hu J., and Vanderstraeten S. Mitochondrial DNA mutators. Cell. Mol. Life Sci. 61 (2004) 2799-2811
29. Fruhwald, M.C., Hasselblatt, M., Wirth, S., Kohler, G., Schneppenheim, R., Subero, J.I., Siebert, R., Kordes, U., Jurgens, H., Vormoor, J., 2005, Non-linkage of familial rhabdoid tumors to SMARCB1 implies a second locus for the rhabdoid tumor predisposition syndrome. Pediatr. Blood Cancer.
30. Fuzesi L., Frank D., Nguyen C., Ringert R.H., Bartels H., and Gunawan B. Losses of 1p and chromosome 14 in renal oncocytomas. Cancer Genet. Cytogenet. 60 (2005) 120-125
31. Galban S., Fan J., Martindale J.L., Cheadle C., Hoffman B., Woods M.P., Temeles G., Brieger J., Decker J., and Gorospe M. von Hippel-Lindau protein-mediated repression of tumor necrosis factor alpha translation revealed through use of cDNA arrays. Mol. Cell. Biol. 23 (2003) 2316-2328
32. Geschwind J.F., Georgiades C.S., Ko Y.H., and Pedersen P.L. Recently elucidated energy catabolism pathways provide opportunities for novel treatments in hepatocellular carcinoma. Expert Rev. Anticancer Ther. 4 (2004) 449-457
33. Gnarra J.R., Tory K., Weng Y., Schmidt L., Wei M.H., Li H., Latif F., Liu S., Chen F., Duh F.M., Lubensky I., Duan D.R., Florence C., Pozzatti R., Walther M.M., Bander N.H., Grossman H.B., Brauch H., Pomer S., Brooks J.D., Isaacs W.B., Lerman M.I., Zbar B., and Linehan W.M. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat. Genet. 7 (1994) 85-90
34. Gong Y., and Agani F.H. Oligomycin inhibits HIF-1alpha expression in hypoxic tumor cells. Am. J. Physiol. Cell Physiol. 288 (2005) C1023-C1029
35. Gopalakrishna R., and Jaken S. Protein kinase C signaling and oxidative stress. Free Radic. Biol. Med. 28 (2000) 1349-1361
36. Gottlieb E., and Tomlinson I.P. Mitochondrial tumour suppressors: a genetic and biochemical update. Nat. Rev. Cancer 11 (2005) 857-866
37. Gu F.L., Cai S.L., Cai B.J., and Wu C.P. Cellular origin of renal cell carcinoma-an immunohistological study on monoclonal antibodies. Scand. J. Urol. Nephrol. 138 Suppl. (1991) 203-206
38. Gurgey A., Ozalp I., Rotig A., Coskun T., Tekinalp G., Erdem G., Akeoren Z., Caglar M., and Bakkaloglu A. A case of Pearson syndrome associated with multiple renal cysts. Pediatr. Nephrol. 10 (1996) 637-638
39. Gwak G.Y., Yoon J.H., Kim K.M., Lee H.S., Chung J.W., and Gores G.J. Hypoxia stimulates proliferation of human hepatoma cells through the induction of hexokinase II expression. J. Hepatol. 42 (2005) 358-364
40. Hervouet E., Demont J., Pecina P., Vojtiskova A., Houstek J., Simonnet H., and Godinot C. A new role for the von Hippel-Lindau tumor suppressor protein: stimulation of mitochondrial oxidative phosphorylation complex biogenesis. Carcinogenesis 26 (2005) 531-539
41. Horton T.M., Petros J.A., Heddi A., Shoffner J., Kaufman A.E., Graham Jr. S.D., Gramlich T., and Wallace D.C. Novel mitochondrial DNA deletion found in a renal cell carcinoma. Genes Chromosomes Cancer 15 (1996) 95-101
42. Hung N.A. Congenital clear cell sarcoma of the kidney. Virchows Arch. 446 (2005) 566-568
43. Jakate S.M., Marsden H.B., and Ingram L. Primary rhabdoid tumour of the brain. Virchows Arch. A Pathol. Anat. Histopathol. 412 (1988) 393-397
44. Jiang Y., Zhang W., Kondo K., Klco J.M., St Martin T.B., Dufault M.R., Madden S.L., Kaelin Jr. W.G., and Nacht M. Gene expression profiling in a renal cell carcinoma cell line: dissecting VHL and hypoxia-dependent pathways. Mol. Cancer Res. 1 (2003) 453-462
45. Kaelin W.G. Proline hydroxylation and gene expression. Annu. Rev. Biochem. 74 (2005) 115-128
46. Kang D., and Hamasaki N. Alterations of mitochondrial DNA in common diseases and disease states: aging, neurodegeneration, heart failure, diabetes, and cancer. Curr. Med. Chem. 12 (2005) 429-441
47. Kelly D.P., and Scarpulla R.C. Transcriptional regulatory circuits controlling mitochondrial biogenesis and function. Genes Dev. 18 (2004) 357-368
48. Kelly J.D., Dai J., Eschwege P., Goldberg J.S., Duggan B.P., Williamson K.E., Bander N.H., and Nanus D.M. Downregulation of Bcl-2 sensitises interferon-resistant renal cancer cells to Fas. Br. J. Cancer 91 (2004) 164-170
49. Ko Y.H., Smith B.L., Wang Y., Pomper M.G., Rini D.A., Torbenson M.S., Hullihen J., and Pedersen P.L. Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem. Biophys. Res. Commun. 324 (2004) 269-275
50. Koller A., Kain R., Haitel A., Mazal P.R., Asboth F., and Susani M. Renal oncocytoma with prominent intracytoplasmic vacuoles of mitochondrial origin. Histopathology 37 (2000) 264-268
51. Kondo K., Kim W.Y., Lechpammer M., and Kaelin Jr. W.G. Inhibition of HIF-2 alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol. 1 (2003) E83
52. Kovacs A., Storkel S., Thoenes W., and Kovacs G. Mitochondrial and chromosomal DNA alterations in human chromophobe renal cell carcinomas. J. Pathol. 167 (1992) 273-277
53. Kovacs G., Akhtar M., Beckwith B.J., Bugert P., Cooper C.S., Delahunt B., Eble J.N., Fleming S., Ljungberg B., Medeiros L.J., Moch H., Reuter V.E., Ritz E., Roos G., Schmidt D., Srigley J.R., Storkel S., van den Berg E., and Zbar B. The Heidelberg classification of renal cell tumours. J. Pathol. 183 (1997) 131-133
54. Krishnan B., and Truong L.D. Renal epithelial neoplasms: the diagnostic implications of electron microscopic study in 55 cases. Hum. Pathol. 33 (2002) 68-79
55. Lee M.S., Kim J.Y., and Park S.Y. Resistance of rho(0) cells against apoptosis. Ann. NY Acad. Sci. 1011 (2004) 146-153
56. Larsson N.G., Oldfors A., Holme E., and Clayton D.A. Low levels of mitochondrial transcription factor A in mitochondrial DNA depletion. Biochem. Biophys. Res. Commun. 200 (1994) 1374-1381
57. Lemasters J.J. Selective mitochondrial autophagy, or mitophagy, as a targeted defense against oxidative stress, mitochondrial dysfunction, and aging. Rejuv. Res. 8 (2005) 3-5
58. Linehan W.M., Walther M.M., and Zbar B. The genetic basis of cancer of the kidney. J. Urol. 70 (2003) 2163-2172
59. Linehan W.M., Vasselli J., Srinivasan R., Walther M.M., Merino M., Choyke P., Vocke C., Schmidt L., Isaacs J.S., Glenn G., Toro J., Zbar B., Bottaro D., and Neckers L. Genetic basis of cancer of the kidney: disease-specific approaches to therapy. Clin. Cancer Res. 10 (2004) 6282S-6289S
60. Linehan W.M., Grubb R.L., Coleman J.A., Zbar B., and Walther M. The genetic basis of cancer of kidney cancer: implications for gene-specific clinical management. BJU Int. 95 Suppl. 2 (2005) 2-7
61. Lu H., Dalgard C., Mohyeldin A., McFate T., Tait A.S., and Verma A. Reversible inactivation of HIF-1 prolyl hydroxylases allows cell metabolism to control basal HIF-1. J. Biol. Chem. 280 (2005) 41928-41939
62. Maher E.R. Von Hippel-Lindau disease. Curr. Mol. Med. 4 (2004) 833-842
63. Maranchie J.K., Afonso A., Albert P.S., Kalyandrug S., Phillips J.L., Zhou S., Peterson J., Ghadimi B.M., Hurley K., Riss J., Vasselli J.R., Ried T., Zbar B., Choyke P., Walther M.M., Klausner R.D., and Linehan W.M. Solid renal tumor severity in von Hippel-Lindau disease is related to germline deletion length and location. Hum. Mutat. 23 (2004) 40-46
64. Martindale J.L., and Holbrook N.J. Cellular response to oxidative stress: signaling for suicide and survival. J. Cell Physiol. 192 (2002) 1-15
65. Maschek G., Savaraj N., Priebe W., Braunschweiger P., Hamilton K., Tidmarsh G.F., De Young L.R., and Lampidis T.J. 2-deoxy-d-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res. 64 (2004) 31-34
66. Maxwell P.H. The HIF pathway in cancer. Semin. Cell Dev. Biol. 16 (2005) 523-530
67. Maxwell P.H., Wiesener M.S., Chang G.W., Clifford S.C., Vaux E.C., Cockman M.E., Wykoff C.C., Pugh C.W., Maher E.R., and Ratcliffe P.J. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399 (1999) 271-275
68. Maynard M.A., Qi H., Chung J., Lee E.H., Kondo Y., Hara S., Conaway R.C., Conaway J.W., and Ohh M. Multiple splice variants of the human HIF-3 alpha locus are targets of the von Hippel-Lindau E3 ubiquitin ligase complex. J. Biol. Chem. 278 (2003) 11032-11040
69. Meierhofer D., Mayr J.A., Foetschl U., Berger A., Fink K., Schmeller N., Hacker G.W., Hauser-Kronberger C., Kofler B., and Sperl W. Decrease of mitochondrial DNA content and energy metabolism in renal cell carcinoma. Carcinogenesis 25 (2004) 1005-1010
70. Meloni-Ehrig A.M. Renal cancer: cytogenetic and molecular genetic aspects. Am. J. Med. Genet. 115 (2002) 164-172
71. Mizutani Y., Nakanishi H., Yamamoto K., Li Y.N., Matsubara H., Mikami K., Okihara K., Kawauchi A., Bonavida B., and Miki T. Downregulation of Smac/DIABLO expression in renal cell carcinoma and its prognostic significance. J. Clin. Oncol. 23 (2005) 448-454
72. Modica-Napolitano J.S., and Singh K.K. Mitochondrial dysfunction in cancer. Mitochondrion 4 (2004) 755-762
73. Moore L.E., Wilson R.T., and Campleman S.L. Lifestyle factors, exposures, genetic susceptibility, and renal cell cancer risk: a review. Cancer Invest. 23 (2005) 240-255
74. Motzer R.J., Bacik J., and Mazumdar M. Prognostic factors for survival of patients with stage IV renal cell carcinoma: memorial sloan-kettering cancer center experience. Clin. Cancer Res. 10 (2004) 6302S-6303S
75. Mukunyadzi P., Huang H., Liu K., and Fan C.Y. Concomitant loss of mitochondria and the DNA repair protein hOGG1 in clear cell carcinoma of the kidney. Appl. Immunohistochem. Mol. Morphol. 11 (2003) 334-338
76. Nagy A., Wilhelm M., Sukosd F., Ljungberg B., and Kovacs G. Somatic mitochondrial DNA mutations in human chromophobe renal cell carcinomas. Genes Chromosom. Cancer 35 (2002) 256-260
77. Nagy A., Wilhelm M., and Kovacs G. Mutations of mtDNA in renal cell tumours arising in end-stage renal disease. J. Pathol. 199 (2003) 237-242
78. Neumann H.P., Pawlu C., Peczkowska M., Bausch B., McWhinney S.R., Muresan M., Buchta M., Franke G., Klisch J., Bley T.A., Hoegerle S., Boedeker C.C., Opocher G., Schipper J., Januszewicz A., Eng C., and European-American Paraganglioma Study Group. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. J. Am. Med. Assoc. 292 (2004) 943-945
79. Oberley L.W. Mechanism of the tumor suppressive effect of MnSOD overexpression. Biomed. Pharmacother. 59 (2005) 143-148
80. Ogilvie I., Kennaway N.G., and Shoubridge E.A. A molecular chaperone for mitochondrial complex I assembly is mutated in a progressive encephalopathy. J. Clin. Invest. 115 (2005) 2784-2792
81. Okamoto K., Toyokuni S., Uchida K., Ogawa O., Takenewa J., Kakehi Y., Kinoshita H., Hattori-Nakakuki Y., Hiai H., and Yoshida O. Formation of 8-hydroxy-2′-deoxyguanosine and 4-hydroxy-2-nonenal-modified proteins in human renal-cell carcinoma. Int. J. Cancer 58 (1994) 825-829
82. Pedersen P.L., Mathupala S., Rempel A., Geschwind J.F., and Ko Y.H. Mitochondrial bound type II hexokinase: a key player in the growth and survival of many cancers and an ideal prospect for therapeutic intervention. Biochim. Biophys. Acta 1555 (2002) 14-20
83. Pelicano H., Carney D., and Huang P. ROS stress in cancer cells and therapeutic implications. Drug Resist. Updat. 7 (2004) 97-110
84. Perlman E.J. Pediatric renal tumors: practical updates for the pathologist. Pediatr. Dev. Pathol. 8 (2005) 320-338
85. Raval R.R., Lau K.W., Tran M.G., Sowter H.M., Mandriota S.J., Li J.L., Pugh C.W., Maxwell P.H., Harris A.L., and Ratcliffe P.J. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol. Cell Biol. 25 (2005) 5675-5686
86. Rossignol F., de Laplanche E., Mounier R., Bonnefont J., Cayre A., Godinot C., Simonnet H., and Clottes E. Natural antisense transcripts of HIF-1alpha are conserved in rodents. Gene 339 (2004) 121-130
87. Safran M., and Kaelin Jr. G. HIF hydroxylation and the mammalien oxygen-sensing pathway. J. Clin. Invest. 111 (2003) 779-783
88. Sangkhathat S., Kusafuka T., Yoneda A., Kuroda S., Tanaka M., Sakai N., and Fukuzawa M. Renal cell carcinoma in a pediatric patient with an inherited mitochondrial mutation. Pediatr. Surg. Int. 21 (2005) 745-748
89. Sanjuan-Pla A., Cervera A.M., Apostolova N., Garcia-Bou R., Victor V.M., Murphy M.P., and McCreath K.J. A targeted antioxidant reveals the importance of mitochondrial reactive oxygen species in the hypoxic signaling of HIF-1alpha. Fed. Eur. Biochem. Soc. Lett. 579 (2005) 2669-2674
90. Schmoll D., Balabanov S., Schwarck D., Burchell A., Kleist B., Zimmermann U., and Walther R. Differential expression of the subunits of the glucose-6-phosphatase system in the clear cell type of human renal cell carcinoma-no evidence for an overexpression of protein kinase B. Cancer Lett. 167 (2001) 85-90
91. Selak M.A., Armour S.M., MacKenzie E.D., Boulahbel H., Watson D.G., Mansfield K.D., Pan Y., Simon M.C., Thompson C.B., and Gottlieb E. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell. 7 (2005) 77-85
92. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3 (2003) 721-732
93. Sherwood J.B., Bard R., Bhargava M., Burns E.R., and Iqbal M.A. A human adult Wilms' tumor. Histologic, ultrastructural, and cytogenetic analysis. Cancer Genet. Cytogenet. 42 (1989) 35-42
94. Shiao Y.H., Resau J.H., Nagashima K., Anderson L.M., and Ramakrishna G. The von Hippel-Lindau tumor suppressor targets to mitochondria. Cancer Res. 60 (2000) 2816-2819
95. Shidara, Y., Yamagata, K., Kanamori, T., Nakano, K., Kwong, J.Q., Manfredi, G., Oda, H., and Ohta, S., 2005. Positive contribution of pathogenic mutations in the mitochondrial genome to the promotion of cancer by prevention from apoptosis. Cancer Res 65, 1655-1663.
96. Simonnet H., Alazard N., Pfeiffer K., Gallou C., Beroud C., Demont J., Bouvier R., Schagger H., and Godinot C. Low mitochondrial respiratory chain content correlates with tumor aggressiveness in renal cell carcinoma. Carcinogenesis 23 (2002) 759-768
97. Simonnet H., Demont J., Pfeiffer K., Guenaneche L., Bouvier R., Brandt U., Schagger H., and Godinot C. Mitochondrial complex I is deficient in renal oncocytomas. Carcinogenesis 24 (2003) 1461-1466
98. Singh K.K., Kulawiec M., Still I., Desouki M.M., Geradts J., and Matsui S. Inter-genomic cross talk between mitochondria and the nucleus plays an important role in tumorigenesis. Gene 354 (2005) 140-146
99. Smeitink J., Sengers R., Trijbels F., and van den Heuvel L. Human NADH:ubiquinone oxidoreductase. J. Bioenerg. Biomembr. 33 (2001) 259-266
100. Sowter H.M., Raval R.R., Moore J.W., Ratcliffe P.J., and Harris A.L. Predominant role of hypoxia-inducible transcription factor (Hif)-1alpha versus Hif-2alpha in regulation of the transcriptional response to hypoxia. Cancer Res. 63 (2003) 6130-6134
101. Steinberg P., Storkel S., Oesch F., and Thoenes W. Carbohydrate metabolism in human renal clear cell carcinomas. Lab. Invest. 67 (1992) 506-511
102. Tallini G., Ladanyi M., Rosai J., and Jhanwar S.C. Analysis of nuclear and mitochondrial DNA alterations in thyroid and renal oncocytic tumors. Cytogenet. Cell Genet. 66 (1994) 253-259
103. Talon I., Lindner V., Sourbier C., Schordan E., Rothhut S., Barthelmebs M., Lang H., Helwig J.J., and Massfelder T. Antitumor effect of parathyroid hormone-related protein neutralizing antibody in human renal cell carcinoma in vitro and in vivo. Carcinogenesis 27 (2006) 73-83
104. Thrash-Bingham C.A., and Tartof K.D. aHIF: a natural antisense transcript overexpressed in human renal cancer and during hypoxia. J. Natl. Cancer Inst. 91 (1999) 143-151
105. Tickoo S.K., Lee M.W., Eble J.N., Amin M., Christopherson T., Zarbo R.J., and Amin M.B. Ultrastructural observations on mitochondria and microvesicles in renal oncocytoma, chromophobe renal cell carcinoma, and eosinophilic variant of conventional (clear cell) renal cell carcinoma. Am. J. Surg. Pathol. 24 (2000) 1247-1256
106. Tomlinson I.P., Alam N.A., Rowan A.J., Barclay E., Jaeger E.E., Kelsell D., Leigh I., Gorman P., Lamlum H., Rahman S., Roylance R.R., Olpin S., Bevan S., Barker K., Hearle N., Houlston R.S., Kiuru M., Lehtonen R., Karhu A., Vilkki S., Laiho P., Eklund C., Vierimaa O., Aittomaki K., Hietala M., Sistonen P., Paetau A., Salovaara R., Herva R., Launonen V., and Aaltonen L.A. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat. Genet. 30 (2002) 406-410
107. Unwin R.D., Craven R.A., Harnden P., Hanrahan S., Totty N., Knowles M., Eardley I., Selby P.J., and Banks R.E. Proteomic changes in renal cancer and co-ordinate demonstration of both the glycolytic and mitochondrial aspects of the Warburg effect. Proteomics (2003) 1620-1632
108. Urbano A., Lakshmanan U., Choo P.H., Kwan J.C., Ng P.Y., Guo K., Dhakshinamoorthy S., and Porter A. AIF suppresses chemical stress-induced apoptosis and maintains the transformed state of tumor cell. Eur. Mol. Biol. Org. J. 24 (2005) 2815-2826
109. van Spronsen D.J., Mulders P.F., and De Mulder H. Novel treatments for metastatic renal cell carcinoma. Crit. Rev. Oncol. Hematol. 55 (2005) 177-191
110. Vaux E.C., Metzen E., Yeates K.M., and Ratcliffe P.J. Regulation of hypoxia-inducible factor is preserved in the absence of a functioning mitochondrial respiratory chain. Blood 98 (2001) 296-302
111. Velickovic M., Delahunt B., Storkel S., and Grebem S.K. VHL and FHIT loss of heterozygosity is common in all renal cancer morphotypes but differs in pattern and prognostic significance. Cancer Res. 61 (2001) 4815-4819
112. Velickovic M., Delahunt B., McIver B., and Grebe S.K. Intragenic PTEN/MMAC1 loss of heterozygosity in conventional (clear-cell) renal cell carcinoma is associated with poor patient prognosis. Mod. Pathol. 15 (2002) 479-485
113. Vogel R.O., Janssen R.J., Ugalde C., Grovenstein M., Huijbens R.J., Visch H.J., van den Heuvel L.P., Willems P.H., Zeviani M., Smeitink J.A., and Nijtmans L.G. Human mitochondrial complex I assembly is mediated by NDUFAF1. Fed. Eur. Biochem. Soc. J. 272 (2005) 5317-5326
114. Wang V., Davis D.A., Haque M., Huang L.E., and Yarchoan R. Differential gene up-regulation by hypoxia-inducible factor-1alpha and hypoxia-inducible factor-2alpha in HEK293T cells. Cancer Res. 65 (2005) 3299-3306
115. Warburg O. On the origin of cancer cells. Science 123 (1956) 309-314
116. Warburg O., Wind F., and Neglers E. In: Warburg O. (Ed). Metabolism of Tumours (1930), Constable and Co., London 254-270
117. Welter C., Kovacs G., Seitz G., and Blin N. Alterations of mitochondrial DNA in human oncocytomas. Genes Chromosomes Cancer 1 (1989) 79-82
118. Wenger R.H., Stehl D.P., and Camenish G. Integration of oxygen signaling at the consensus HRE. Sci. STKE 306 (2005) 12
119. Wykoff C.C., Sotiriou C., Cockman M.E., Ratcliffe P.J., Maxwell P., Liu E., and Harris A.L. Gene array of VHL mutation and hypoxia shows novel hypoxia-induced genes and that cyclin D1 is a VHL target gene. Br. J. Cancer 90 (2004) 1235-1244
120. Yan Y., Mahotka C., Heikaus S., Shibata T., Wethkamp N., Liebmann J., Suschek C.V., Guo Y., Gabbert H.E., Gerharz C.D., and Ramp U. Disturbed balance of expression between XIAP and Smac/DIABLO during tumour progression in renal cell carcinomas. Br. J. Cancer 91 (2004) 1349-1357
121. Yang J.C. Bevacizumab for patients with metastatic renal cancer: an update. Clin. Cancer Res. 10 (2004) 6367S-6370S
122. Yang, X.J., Tan, M.H., Kim, H.L., Ditlev, J.A., Betten, M.W., Png, C.E., Kort, E.J., Futami, K., Furge, K.A., Takahashi, M., Kanayama, H.O., Tan, P.H., Teh, B.S., Luan, C., Wang, K., Pins, M., Tretiakova, M., Anema, J., Kahnoski, R., Nicol, T., Stadler, W., Vogelzang, N.G., Amato, R., Seligson, D., Figlin, R., Belldegrun, A., Rogers, C.G., Teh, B.T., 2005. A molecular classification of papillary renal cell carcinoma. Cancer Res 65, 5628-5637.
123. Yoshimura H., Dhar D.K., Kohno H., Kubota H., Fujii T., Ueda S., Kinugasa S., Tachibana M., and Nagasue N. Prognostic impact of hypoxia-inducible factors 1alpha and 2alpha in colorectal cancer patients: correlation with tumor angiogenesis and cyclooxygenase-2 expression. Clin. Cancer Res. 10 (2004) 8554-8560
124. Zambrano N.R., Lubensky I.A., Merino M.J., Linehan W.M., and Walther M.M. Histopathology and molecular genetics of renal tumors toward unification of a classification system. J. Urol. 162 (1999) 1246-1258
125. Zanssen S., Gunawan B., Fuzesi L., Warburton D., and Schon E.A. Renal oncocytomas with rearrangements involving 11q13 contain breakpoints near CCND1. Cancer Genet. Cytogenet. 149 (2004) 120-124